Immunohistochemical detection of p53 and bcl-2 proteins in neoplastic and non-neoplastic endocervical glandular lesions

International Journal of Gynecological Pathology

Volumn 16, Issue 1, 1997, Pages 22-27

  McCluggage, W Glenn ^a   McBride, Hilary ^a   Maxwell, Perry ^a   Bharucha, Hoshang ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Adenocarcinoma; bcl 2 protein; Endocervix; Immunohistochemistry; p53 protein

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P53;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ETIOLOGY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA;

EID: 0342547093     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199701000-00004     Document Type: Article

References (30)

1. Benchimol S, Lamb P, Crawford LV, et al. Transformation associated p53 protein is encoded by a gene on human chromosome 17. Sum Cell Mon Gen 1985;11:505-9.
2. Levine AJ, Momant J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
3. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991;253:49-53.
4. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc 70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
5. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
6. Korsmeyer SJ. Bcl-2: a repressor of lymphocyte death. Immunol Today 1992;13:285-8.
7. Gaulard P, d'Agay MF, Peuchmaur M, et al. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992;140: 1089-5.
8. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. Expression in non-Hodgkins lymphoma of the bcl-2 protein associated with the t (14;18) translocation. New Eng J Med 1988;318: 1638-44.
9. Pezzella F, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology 1995;26:89-3.
10. Jeffers MD, Richmond J, Farquharson M, McNicol AM. p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. J Clin Pathol 1994;47: 1073-6.
11. Pollanen R, Soini Y, Vahakangas K, Paako P, Lehto VP. Aberrant p53 protein expression in cervical intra-epithelial neoplasia. Histopathology 1993;23:471-4.
12. Holm R, Skomedal H, Heiland A, Kristensen G, Borresen AL, Nesland JM. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant and malignant tissues of the cervix uteri. J Pathol 1993;169:21-26.
13. Bosari S, Roncalli M, Viale G, Bussi P, Coggi G. p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 1993;169:425-0.
14. Heiland A, Holm R, Kristensen G, et al. Genetic alteration of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1973;171:105-14.
15. Cooper K, Herrington S, Evans MF, Gatter K, McGee J. p53 antigen in cervical condylomata, intraepithelial neoplasia, and, carcinoma: relationship to HPV infection and integration. J Pathol 1993;171:27-34.
16. Young RH, Scully RE. Invasive adenocarcinoma and related tumors of the uterine cervix. Semin Diagn Pathol 1990;7:205-7.
17. Jeffers MD, Farquharson MA, Richmond JA, McNicol AM. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. J Pathol 1995;177:65-70.
18. Teneriello MG, Ebina M, Linnoila RI et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53: 3103-3108.
19. Symmans PJ, Linehan JM, Brito MJ, Filipe MI. p53 expression in Barrett's oesophagus, dysplasia and adenocarcinoma using antibody DO-7. J Pathol 1994;173:221-6.
20. Flejou JF, Potet F, Muzeau F, Le Pelletier F, Fekete F, Henin D Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 1993;46:330-3.
21. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ Bcl-2 protein is topographically restricted in tissues characterised by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-5.
22. Charlotte F, L'Hermine A, Martin N, et al. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol 1994;144:460-5.
23. McDonnel TJ, Troncosa P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen - independant prostate cancer. Cancer Res 1992;52:6940-4.
24. Jiang SX, Sato Y, Kuwao S, Kameya T Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995;177:135-8.
25. Zhao M, Zhang NX, Economon M, Blaha I, Laissue JD, Zimmermann A. Immunohistochemical detection of bcl-2 protein in liver lesions; bcl-2 protein is expressed in hepatocellular carcinomas but not in liver cell dysplasia. Histopathology 1994:25:237-5.
26. Joensuu H, Pylkkanen L, Tiokkaneu S, Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145: 1191-8.
27. Pilotti S, Collins P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994;172:337-2.
28. Ismail SM. Cone biopsy causes cervical endometriosis and tubo-endometrial metaplasia. Histopathology 1991;18:107-14.
29. Al-Nafussi A, Rahilly M. The prevalence of tubo-endometrial metaplasia and adenomatoid proliferation. Histopathology 1993; 22:177-9.
30. Gompel A, Sabourin JC, Martin A, et al. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994;144:1195-1202.